BioNTech vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy for 2027?

Résumé détaillé

Vertex Pharmaceuticals earns steady profits from its cystic fibrosis medicines while expanding into new diseases. BioNTech has a large cash cushion and a growing cancer pipeline, but its COVID vaccine sales are fading.

Investors choosing between BioNTech (NASDAQ:BNTX) and Vertex Pharmaceuticals (NASDAQ:VRTX) must weigh the massive potential of mRNA cancer research against the reliable, high-margin cash flows of a dominant cystic fibrosis treatment leader.

BioNTech is famous for its role in COVID-19 vaccines but is now pivoting toward oncology. Vertex Pharmaceuticals dominates the cystic fibrosis market while expanding into new areas like gene therapy. Both companies represent different stages of the biotechnology lifecycle, making them popular comparisons for healthcare investors seeking long-term growth.

BioNTech focuses on developing immunotherapies and mRNA-based medicines for cancer and infectious diseases. In its latest annual report, filed for the period ending December 31, 2025, the company noted it employed roughly 8,052 people. While it gained global fame for its vaccine success, the business strategy now centers on commercializing oncology treatments in the United States and other major global markets.

In FY 2025, revenue reached nearly $3.2 billion, representing growth of approximately 4.3% compared to the previous year. Despite this growth, the company reported a net loss of approximately $1.3 billion for the period. This resulted in a net margin of negative 39.6%, which measures the percentage of revenue remaining after all expenses are accounted for.

As of its December 2025 balance sheet, the company maintained a debt-to-equity ratio of 0.0x, indicating it carries no debt. The current ratio was approximately 7.5x, which measures a company's ability to cover its short-term liabilities with assets. Free cash flow for the year was close to $299.4 million, which is the cash a company generates after accounting for capital expenditures.

Vertex Pharmaceuticals is a global leader focused on treating serious diseases, specifically through its dominant cystic fibrosis franchise.

In FY 2025, revenue reached approximately $12 billion, a growth rate of around 9% over the prior year.

As…

Début de l'article, extrait de Yahoo Finance. Pour lire la suite, ouvrez l'article chez le média.